



# JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,  
Haryana (India)

Ph.: +91 124 4406710; E-mail: [cs@jagsonpal.com](mailto:cs@jagsonpal.com); Website: [www.jagsonpal.com](http://www.jagsonpal.com)  
CIN NO. L74899DL1978PLC009181

July 23, 2025

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Subject: Intimation of Board Meeting under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (“the Company”) is scheduled to be held on Saturday, July 26, 2025 to consider and approve, inter-alia the Unaudited Financial Results of the company for the quarter ended June 30, 2025.

Further, in continuation of our letter dated June 26, 2025 , regarding Intimation of closure of Trading Window, we would like to inform that the trading window for trading in Securities of the company shall remain closed till July 28, 2025.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Pratham Rawal**  
**Company Secretary & Compliance Officer**